Nuwiq®

Human coagulation factor VIII produced in a human cell line by recombinant DNA technology. No animal or human derived materials are added during the manufacturing process or to the final medicinal product.

Indication

Nuwiq® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) of all age groups.

Presentation

Supplied as powder and solvent for solution for injection, with all vial strengths in a 2.5 mL infusion volume and supplied with a pre-filled syringe. Available in vials of: 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU. 

Key features of Nuwiq® 

Convenient twice-weekly dosing to effectively prevent bleeds in patients on personalised prophylaxis1:

• 83% of patients free from spontaneous bleeds;

• 57% of patients treated twice-weekly or less;

• 0 inhibitors or severe treatment related adverse events.

In 66 adult patients with haemophilia A on personalised prophylaxis with Nuwiq®1

Favourable rate of inhibitors in previously untreated patients (PUPs) demonstrated in NuProtect, the largest prospective study in true PUPs with a single FVIII product2:

• 17.6% cumulative incidence of high-titre inhibitors;

• 27.9% cumulative incidence of all inhibitors;

• No inhibitors in patients with non-null F8 mutations.

In 105 PUPs in the NuProtect Study2.

Zero inhibitors in over 190 previously treated patients switching to Nuwiq®  in clinical trials3

References

1. Lissitchkov T et al. Haemophilia 2017; 23:697-704.
2. Liesner R et al. Abstract accepted for presentation at ASH 2019, Orlando, US.  
3. Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.

You are now on Octapharma’s global website. Please select your country from the menu at the top of this page to access more detailed country-specific information or to contact your local Octapharma team.